Clinical Trials Directory

Trials / Completed

CompletedNCT04192994

Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Federal University of São Paulo · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Our study will evaluate the efficacy of early PPV in acute endophthalmitis and attempt to prove its greater effectiveness for combating infection when compared to eyes that received only intravitreal antibiotic therapy

Detailed description

Endophthalmitis, a severe inflammatory ocular condition with profound visual impairment that can lead to irreversible visual loss, requires immediate treatment. The only multicenter randomized trial of different forms of acute endophthalmitis treatment was the Endophthalmitis Vitrectomy Study. The study concluded that intravitreal antibiotic injection improves visual prognosis, and pars plana vitrectomy (PPV) improves the final visual acuity (VA) when performed in patients with light perception or worse VA. Our study will evaluate the efficacy of early PPV in acute endophthalmitis and attempt to prove its greater effectiveness for combating infection when compared to eyes that received only intravitreal antibiotic therapy. Primary Endpoint: The final VA, ocular anatomy, retinal layer anatomy, and ERG response in the intravitreal injection group will be compared with the PPV group. Secondary Endpoint: The final VA, eyeball anatomy, retinal layer anatomy, and ERG response in the group that underwent PPV will be compared with and without oral moxifloxacin therapy.

Conditions

Interventions

TypeNameDescription
DRUGIntravitreal Antibiotic InjectionIntravitreal Antibiotic Injection
PROCEDUREPars Plana VitrectomyPars Plana Vitrectomy

Timeline

Start date
2019-01-01
Primary completion
2020-01-01
Completion
2023-12-01
First posted
2019-12-10
Last updated
2024-05-24

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT04192994. Inclusion in this directory is not an endorsement.